Asad Ismail, MD
Addiction Medicine · Louisville, KYNPI 1144227026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 647 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 26.2% of the total. Among addiction medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$935
- Teva Pharmaceuticals USA, Inc.$839
- Vanda Pharmaceuticals Inc.$695
- Otsuka America Pharmaceutical, Inc.$656
- Indivior Inc.$650
- plus $4K from 31 others
Across 1 payment — averaging $1816.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$9,62596%
- Education$3694%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$104
How this compares
$9,995 in reported general payments places this provider in the 90th percentile of 40 addiction medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 91 | $119,945 |
| AustedoDeutetrabenazine | 12 | $99,682 |
| SpravatoEsketamine Hcl | 55 | $66,961 |
| Abilify MaintenaAripiprazole | 21 | $64,167 |
| CaplytaLumateperone Tosylate | 30 | $43,918 |
| VivitrolNaltrexone Microspheres | 12 | $19,721 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 252 | $14,997 |
| QuviviqDaridorexant Hcl | 27 | $13,165 |
| BelsomraSuvorexant | 17 | $7,525 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 39 | $6,869 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 23 | $5,519 |
| Lurasidone Hcl | 44 | $5,175 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $4,855 |
| QelbreeViloxazine Hcl | 13 | $4,781 |
| Aripiprazole | 29 | $3,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,616 | $119,94591 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $839 | $99,68212 claims |
| Johnson & JohnsonSpravato | $595 | $66,96155 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $656 | $64,16721 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $935 | $43,91830 claims |
| Alkermes, Inc.Vivitrol | $442 | $19,72112 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $32 | $13,16527 claims |
| Orexo US, Inc.Zubsolv | $17 | $5,51923 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $116 | $4,78113 claims |
| Lilly USA, LLCOlanzapine | $45 | $2,14591 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 40 addiction medicine providers in Kentucky.
Other addiction medicine in Louisville
- Kathryn RutlandLouisville$3K
- David AndersonLouisville$2K
- Richard CalesLouisville$1K
- Julia SchroederLouisville$695
- John StockingLouisville$534
- Stuart UrbachLouisville$124
- Allison KoetterLouisville$106
- Nanine HendersonLouisville$92
- Stephanie WaltonLouisville$60
- Irwin CohenLouisville$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.